samedan logo
 
 
spacer
home > epc > summer 2018 > a blemish on good science
PUBLICATIONS
European Pharmaceutical Contractor

A Blemish on Good Science

In scientific research, objective data collection is critical to making conclusions that are free from bias. The importance of minimising subjectivity is particularly important in dermatology clinical trials where clinically acceptable methods of assessing disease symptoms or treatment response are largely based on a physician’s subjective assessment.

Dermatologists assess skin lesions and treatment responses using different observer-rated scales, such as the Eczema Area and Severity Index (EASI) and the Psoriasis Area and Severity Index (PASI). Both rely on visual assessments of symptoms, such as erythema (redness). This traditional approach of ‘eye-balling lesions’ results in subjective measurements prone to inter- and intra-observer variability (1). They can even vary at different times of the day.

Developing processes to objectively measure outcomes in dermatology clinical trials should be a priority for sponsors and investigators in this field. Thought leaders, including Dr James Milbauer, believe that, in the not-too-distant future, imaging technology and software will enable clinicians to scan, measure, and objectively assess patients and clinical trial participants (2). Until this technology becomes a reality, the pharmaceutical industry will continue to rely on alternative established strategies to mitigate the current lack of objectivity in measuring outcomes for dermatology trials. This article will discuss these strategies and the research that has created the first steps towards objective measurements for dermatology trials.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Elisabeth Rowold, Director of Project Management in the dermatology division (Europe), has more than 23 years of experience in the pharma industry and more than 14 years of experience in the conduct and oversight of clinical trials spanning all phases of cutaneous safety and efficacy studies. Elisabeth oversees the Novella Project Management activities in Europe and is responsible for providing strategic leadership, organisation, training, and ongoing evaluation and support to the Clinical Operations group.
spacer
Dr Elisabeth Rowold
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Change of Company Name: VTU Technology is now VALIDOGEN

VTU Technology GmbH, a leading, globally acting Austrian biotech contract research company developing microbial strains and processes for the production of recombinant proteins, announced today the change of its company name to VALIDOGEN GmbH following a reorganization of VTU Holding GmbH.
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 
Industry Events

PDA Parenteral Packaging 2019

19-20 March 2019, Hilton Molino Stucky, Venice, Italy

PDA Europe’s Conference has become a must-attend event for all professionals in the Parenteral Packaging arena. Join us in Venice in March 2019 to continue and further deepen scientific advancements and our ongoing professional discourse of latest on primary packaging technologies and business trends. This conference and the accompanying exhibition address quality of components and cont­ainers, container closure development and integrity testing as well as aspects of processing, product distribution and storage.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement